FeesSafety
Pluang+

Minerva Neurosciences to present at 2026 Jefferies Global Healthcare Conference in London

Market News
29 Oct 2026, 14:00 WIB
GlobeNewsWire
View Source
Neutral
Minerva Neurosciences to present at 2026 Jefferies Global Healthcare Conference in London

Minerva Neurosciences, a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, will participate in the 2026 Jefferies Global Healthcare Conference in London on November 16-17. The company's management will engage in a fireside chat and one-on-one meetings to discuss their ongoing Phase 3 trial of roluperidone for negative symptoms of schizophrenia. This event provides Minerva an opportunity to update investors and stakeholders on their clinical progress and future plans. The sessions will be webcast live and available for replay on Minerva's website.

Minerva Neurosciences' participation in the 2026 Jefferies Global Healthcare Conference is contextually framed by Pluang's health sector data. As of Oct 29, 2026 17:11 WIB, 86 of 150 priced health-sector US stocks rose while 57 fell. Notable movers include Gilead Sciences at USD 163.77 with a 2.87% increase and a typical hold time of 114 days on Pluang.

More News

AdvantageLumber.com launches free Sketch-A-Deck tool for easy deck design and instant material estimates

AdvantageLumber.com launches free Sketch-A-Deck tool for easy deck design and instant material estimates

AdvantageLumber.com has introduced Sketch-A-Deck, a free online software that simplifies deck design for homeowners and contractors. The tool allows users to draw custom deck layouts, attach them to their homes, and generate build-ready plans with de...

Others
Bullish
23 minutes ago
Industrial Control System Security Market to nearly double to $38.48B by 2031 with 16.5% CAGR

Industrial Control System Security Market to nearly double to $38.48B by 2031 with 16.5% CAGR

The global Industrial Control System (ICS) Security Market is projected to grow from $17.91 billion in 2026 to $38.48 billion by 2031, at a CAGR of 16.5%. This growth is driven by rising cyberattacks targeting critical infrastructure and the increasi...

Market News
Bullish
23 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App